Skip to Main Content


Yale Cancer Center Announces New Leadership Appointments

February 09, 2022

Yale Cancer Center is pleased to announce three new leadership appointments to continue to build and support our internationally-recognized cancer research program.

Mark A. Lemmon, PhD, FRS, David A. Sackler Professor of Pharmacology, Professor of Molecular Biophysics and Biochemistry, and Co-Director of the Cancer Biology Institute, has been appointed Deputy Director of Yale Cancer Center (YCC). Lemmon joined YCC in 2015 to bring the concept of the Cancer Biology Institute on Yale West Campus to reality and has assembled a team of basic science faculty in the Institute who are all members of YCC research programs.

“Dr. Lemmon’s efforts to enhance interactions between basic, translational, population, and clinical investigators across the YCC community in his former role as Associate Cancer Center Director for Basic Science have strengthened research collaborations,” said Eric P. Winer, MD, Director of YCC and Physician-in-Chief of Smilow Cancer Hospital.

After 11 years as Deputy Director of YCC, Daniel C. DiMaio, MD, PhD, Waldemar Von Zedtwitz Professor of Genetics and Professor of Molecular Biophysics and Biochemistry and of Therapeutic Radiology, has been named Senior Advisor to the Director. “Dr. DiMaio’s vision, commitment, and support of the YCC leadership team is invaluable,” said Winer. “His guidance during YCC Support Grant submissions and his historical knowledge will continue to provide us with a foundation for success.”

Megan C. King, PhD, Associate Professor of Cell Biology and of Molecular, Cellular, and Development Biology, has been named Associate Cancer Center Director for Basic Science. King has served as Co-Leader of the Radiobiology & Radiotherapy Research Program since 2019. In her new role as Associate Cancer Center Director for Basic Science, King will oversee YCC basic science priorities across the YCC community. King’s research is generating unique insights into chromatin organization and dynamics, with a focus on DNA repair and the biology of BRCA cancer susceptibility genes. “Dr. King is a prominent addition to our leadership team,” said Winer. “I look forward to working together with her to expand the impact of our basic science research to help patients with cancer.”

Submitted by Anne Doerr on February 10, 2022